Participants 60 92 3
anti-herpes virus therapy in MS.
Participants 149 305 5
antiherpes drug valacyclovir on MRI-evident lesions in patients with relapsing-remitting MS in a phase 2, randomized, double-blind, placebo-controlled study
Participants 443 559 7
Patients were eligible for the study if they had had two or more MS relapses in the 2-year period before enrollment.
Participants 560 750 6
Seventy patients with Expanded Disability Status Scale scores of 0 to 5.5 were randomly assigned to receive 1 gram of valacyclovir (n = 36) or placebo (n = 34) three times daily for 24 weeks
Participants 1892 1991 3
patients with relapsing-remitting MS who had two or more relapses during the previous 2-year period
